Your browser doesn't support javascript.
loading
Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
Takeuchi, Tsutomu; Nishikawa, Kiyohiro; Yamada, Fumika; Ohshima, Shiro; Inoue, Makoto; Yoshioka, Yutaka; Yamanaka, Hisashi.
Affiliation
  • Takeuchi T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Nishikawa K; Quality & Pharmacovigilance Division, Pharmaceuticals Group, Nippon Kayaku Co., Ltd., Tokyo, Japan.
  • Yamada F; Asajes Ventures,Tokyo, Japan.
  • Ohshima S; Quality & Pharmacovigilance Division, Pharmaceuticals Group, Nippon Kayaku Co., Ltd., Tokyo, Japan.
  • Inoue M; Department of Rheumatology and Allergology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan.
  • Yoshioka Y; Department of Rheumatology, Inoue Hospital, Takasaki, Gunma, Japan.
  • Yamanaka H; Department of Rheumatology, Handa City Hospital, Handa, Aichi, Japan.
Mod Rheumatol ; 32(4): 718-727, 2022 Jul 01.
Article in En | MEDLINE | ID: mdl-34918129
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Antirheumatic Agents / Biosimilar Pharmaceuticals / Antibodies, Monoclonal Limits: Humans Country/Region as subject: Asia Language: En Journal: Mod Rheumatol Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Antirheumatic Agents / Biosimilar Pharmaceuticals / Antibodies, Monoclonal Limits: Humans Country/Region as subject: Asia Language: En Journal: Mod Rheumatol Year: 2022 Document type: Article Affiliation country: Country of publication: